Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 8, 2003, Pages 763-768

  Rosenblatt, Karin A ^a   Carter, Joseph J ^b   Iwasaki, Lori M ^b   Galloway, Denise A ^b   Stanford, Janet L ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; MALE; POPULATION; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; SEROLOGY; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; UNITED STATES; VIRUS INFECTION; WART VIRUS;

ADULT; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PAPILLOMAVIRUS INFECTIONS; PROSTATIC NEOPLASMS; RISK FACTORS; SEROLOGIC TESTS;

EID: 0041525333     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Strickler, H. D., and Goedert, J. J. Sexual behavior and evidence for an infectious cause of prostate cancer. Epidemiol. Rev., 23: 144-151, 2001.
2. Rosenblatt, K. A., Wicklund, K. G., and Stanford, J. L. Sexual factors and the risk of prostate cancer. Am. J. Epidemiol., 153: 1152-1158, 2001.
3. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 64, Human papillomaviruses. Lyon, France: IARC, 1995.
4. Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., and Shah, K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J. Natl. Cancer Inst. (Bethesda), 87: 779-780, 1995.
5. Dillner, J., Knekt, P., Boman, J., Lehtinen, M., Af Geijersstam, V., Sapp, M., Schiller, J., Maatela, J., and Aromaa, A. Sero-epidemiological association between human-papillomavirus infection and risk of prostate cancer. Int. J. Cancer, 75: 564-567, 1998.
6. Hisada, M., Rabkin, C. S., Strickler, H. D., Wright, W. E., and Christianson, R. E. Human papillomavirus antibody and risk of prostate cancer. J. Am. Med. Assoc., 283: 340-341, 2000.
7. Strickler, H. D., Burk, R., Shah, K., Viscidi, R., Jackson, A., Pizza, G., Bertoni, F., Schiller, J. T., Manns, A., Metcalf, R., Qu, W., and Goedert, J. J. A multifaceted study of human papillomavirus and prostate carcinoma. Cancer (Phila.), 82: 1118-1125, 1998.
8. Strickler, H. D., Schiffman, M. H., Shah, K. V., Rabkin, C. S., Schiller, J. T., Wacholder, S., Clayman, B., and Viscidi, R. P. A survey of human papillomavirus 16 antibodies in patients with epithelial cancers. Eur. J. Cancer, 7: 305-313, 1998.
9. Hayes, R. B., Pottern, L. M., Strickler, H., Rabkin, C., Pope, V., Swanson, G. M., Greenberg, R. S., Schoenberg, J. B., Liff, J., Schwartz, A. G., Hoover, R. N., and Fraumeni, J. F. Sexual behaviour, STDs and risks for prostate cancer. Br. J. Cancer, 82: 718-725, 2000.
10. Stanford, J. L., Wicklund, K. G., McKnight, B., Daling, J. R., and Brawer, M. K. Vasectomy and risk of prostate cancer. Cancer Epidemiol. Biomark. Prev., 8: 881-886, 1999.
11. Waksberg, J. Sampling methods for random digit dialing. J. Am. Stat. Assoc., 73: 40-46, 1978.
12. Patterson, R. E., Kristal, A. R., Carter, R. A., Fels-Tinker, L., Bolton, M. P., and Agurs-Collins, T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann. Epidemiol., 9: 178-187, 1999.
13. Gleason, D. F., and the V. A. Cooperative Urological Research Group. Histologic grading and clinical staging of prostatic carcinoma. In: Urologic Pathology: The Prostate. M. Tannenbaum (ed.) Philadelphia: Lea and Febiger, 171-197, 1977.
14. Carter, J. J., Koutsky, L. A., Hughes, J. P., Lee, S. K., Kuypers, J., Kiviat, N., and Galloway, D. A. Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J. Infect. Dis., 181: 1911-1919, 2000.
15. Roden, R. B., Armstrong, A., Haderer, P., Christensen, N. D., Hubbert, N. L., Schiller, J. T., and Kimbauer, R. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J. Virol., 71: 6247-6252, 1997.
16. Wang, Z., Christensen, N., Schiller, J. T., and Dillner, J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J. Gen. Virol., 78: 2209-2215, 1997.
17. Hagensee, M. E., Yaegashi, N., and Galloway D. A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone of by coexpression of the L1 and L2 capsid proteins. J. Virol 67: 315-322, 1993.
18. Breslow, N. E., and Day, N. E. Statistical Methods in Cancer Research, Vol. 1. The Analysis of Case-Control Studies. Lyon France: IARC, 1980.
19. Dubin, N., and Pastemack, B. S. Risk assessment for case-control subgroups by polychotomous logistic regression. Am. J. Epidemiol., 123: 1101-1117, 1986.
20. Armitage, P. Tests for linear trend in proportions and frequencies. Biometrics, 11: 375-386, 1955.
21. Mehta, C. R., and Patel, N. R. A network algorithm for performing Fisher's exact test in r x c contingency tables. J. Am. Stat. Assoc., 78: 427-434, 1983.
22. Af Geijersstam, V., Kibur, M., Wang, Z., Koskela, P., Pukkala, E., Schiller, J., Lehtinen, M., and Dillner, J. Stability over time of serum antibody levels to human papillomavirus type 16. J. Infect. Dis., 177: 1710-1714, 1998.
23. Shah, K. V., Viscidi, R. P., Alberg, A. J., Helzlsouer, K. J., and Comstock, G. W. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol. Biomark. Prev., 6: 233-237, 1997.
24. Strickler, H. D., Kirk, G. D., Figueroa, P., Ward, E., Braith, A. R., Escoffery, C., Drummond, J., Goebel, B., Waters, D., McClimens, R., and Manns, A. HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int. J. Cancer, 80: 339-344, 1999.
25. Carter, J. J., Madeleine, M. M., Shera, K., Shera, K., Schwartz, S. M., Cushing-Haugen, K. L., Wipf, G. C., Porter, P., Daling, J. R., McDougal, J. K., and Galloway, D. A. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res., 61: 1934-1940, 2001.
26. Schwartz, S. M., Daling, J. R., Doody, D. R., Wipf, G. C., Carter, J. J., Madeleine, M. M., Mao, E. J., Fitzgibbons, E. D., Huang, S., Beckmann, A. M., McDougall, J. K., and Galloway, D. A. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J. Natl. Cancer Inst. (Bethesda), 90: 1626-1636, 1998.
27. Svare, E. I., Kjaer, S. K., Worm, A. M., Moi, H., Christensen, R. B., van den Brule, A. J., Walboomers, J. M., Meijer, C. J., Hubbert, N. L., Lowry, D. R., and Schiller, J. T. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J. Infect. Dis., 176: 876-883, 1997.